
    
      The study will evaluate the tolerability, safety, and feasibility of combination bevacizumab
      and capecitabine in a small number of frail patients with metastatic colorectal cancer who
      have a compromised performance status. Preclinical studies suggest that the combination of
      chemotherapy and anti-angiogenic therapy offer an increased anti-tumor effect compared with
      either treatment alone.
    
  